It could be (cautiously) concluded that biomarkers from the RAS-RAF-MAPK cascade and an activated PI3K-PTEN-AKT signaling pathway may not be able to fully unravel the complexity and versatility of the aspirin effect on cancer. This evidence concerns the gene AKT1 and cancer.